Iomai and Merck work together to test new vaccine patch
WASHINGTON Iomai Corp. made an agreement with Merck to study Iomai’s new vaccine that does not provide a needle for treatment, but a patch, according to published reports.
Treatment for the patch is given by placing it over an area where one would place a vaccine injection, and the vaccine would pass through the skin and reach certain cells to boost the immune system.
An earlier study, which sparked original interest in the new technology, included a 500-person clinical trial that showed that one dose of the vaccine patch was able to protect patients from pandemic flu, and was needed only once, as opposed to the injection, which needed two doses to have the same results, according to published reports,
The terms of Iomai and Merck’s agreement were not made public, but Merck does have first option to choose an exclusive licensing agreement for the vaccine patch.
Study shows no increased heart risk for newborns with mothers on Paxil
TORONTO According to a new study published in the American Journal of Psychiatry, infants whose mothers took the GlaxoSmithKline antidepressant drug Paxil during early pregnancy do not have an increased risk of heart defects.
The study was performed by the Motherisk program at the Hospital for Sick Children and University of Toronto. Almost 1,200 infants were studied and the results showed that infants who had been exposed to the medication had the same risk for the defects as infants not exposed, 0.7 percent.
GSK had originally published a report stating that risk of cardiovascular defects was 2 percent. Adrienne Einarson, the lead author of the new report called GSK’s initial report, “preliminary information.” GSK later adjusted its figure to 1.5 percent.
In general, the incidence of heart defects in the general population is about 1 percent.
Personal injury lawsuit filed against makers of contaminated drug Heparin
CAMDEN, N.J. A personal lawsuit against Baxter Healthcare has been filed following a near fatal reaction to the contaminated prescription drug Heparin, according to published reports.
Accounts of deaths and hundreds of severe allergic reactions stemmed from an active ingredient in the drug, which was identified as a chemically altered form of chondroitin sulfate. According to published reports, the chemical serves as a dietary supplement made from animal cartilage that is used to treat joint pain.
The contamination was rooted in China, where the drug is manufactured. The Federal Drug Administration filed a report on March 19 alerting the public of the dangers of taking the Heparin, and the medications were almost immediately recalled as a result.
“Prescription drug manufacturers have a duty to produce products that are safe and free of dangerous ingredients,” stated Wendy Fleishman of the New York City office of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein. “Only through a lawsuit or otherwise making a claim against Baxter can patients obtain compensation for their injuries. The American public needs the drug companies, like Baxter, to take responsibility for the safety of their products—especially those like Heparin, which are manufactured in part in China.”
The suit claims that Baxter did not adequately inspect the product before selling it, making them negligent, and as a result contributing to many unnecessary deaths.